CN102603607B - Preparation method of (R)-oxiracetam - Google Patents
Preparation method of (R)-oxiracetam Download PDFInfo
- Publication number
- CN102603607B CN102603607B CN201110024526.XA CN201110024526A CN102603607B CN 102603607 B CN102603607 B CN 102603607B CN 201110024526 A CN201110024526 A CN 201110024526A CN 102603607 B CN102603607 B CN 102603607B
- Authority
- CN
- China
- Prior art keywords
- ethyl ester
- oxiracetam
- exchange resin
- glycine ethyl
- thick product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A preparation method of (R)-oxiracetam comprises the following steps: taking glycine ethyl ester hydrochloride and (R)-4-halo-3-hydroxyl-ethyl butyrate as raw materials to react in an alcohol solvent under an alkali condition, washing with inorganic alcohol, concentrating, extracting and separating, introducing ammonia water to prepare a crude product of oxiracetam, and purifying the crude product, wherein glycine ethyl ester hydrochloride is firstly dissociated by diethyl ether and ammonia into glycine ethyl ester. According to the invention, the main raw materials are (R)-4-halo-3-hydroxyl-ethyl butyrate and glycine ethyl ester hydrochloride, and are cheap, easily accessible, environment-friendly and pollution-free; and the glycine ethyl ester hydrochloride is firstly dissociated, so that the use amount of the materials in the reaction is effectively reduced, the cost is reduced and the yield of the reaction is improved. The prepared (R)-oxiracetam is low in cost, high in yield which can reach 33%, and mild in reaction condition which is beneficial for industrial production in large scale. The HPLC (high performance liquid chromatography) purity of the prepared (R)-oxiracetam product reaches more than 98.5%.
Description
Technical field
The present invention relates to the preparation of oxiracetam, be specifically related to the preparation method of one (R)-oxiracetam.
Background technology
Oxiracetam (oxiracetam), be by Italian SmithKline Bi Qiemu company in 1974 synthetic nootropics first, this medicine went on the market in Italy in 1987, the raceme that oxiracetam is made up of two kinds of isomer (S)-oxiracetam ((S)-oxiracetam) and (R)-oxiracetam ((R)-oxiracetam).(R)-oxiracetam is a single enantiomer of oxiracetam, and chemistry is by name: (R)-Esomeprazole.Nootropics oxiracetam is a kind of synthetic hydroxy-amino-butyric acid (GABOB) derivative, and it is that a kind of can promotion learnt, memory, the medicine for central nervous system of protection injured nerve cell.
The United States Patent (USP) 4,124,594,4,173,569 and 4,629 of authorizing I.S.F.Spa, 797 disclose a kind of method of preparing the pure oxyracetam of optically-active.In these patents, disclosed method comprises and makes pure (the s)-γ of optically-active amino-beta--hydroxybutyric acid react to protect hydroxyl with silylating reagent, makes products therefrom under acid acceptor exists, represent the formula Hal (CH of halogen atom with Hal wherein
2c00R) aliphatic acid halogen compounds reaction, then obtains the pure oxyracetam of optically-active through cyclisation and hydrolysis.Although the method provides optically-active pure oxyracetam, its shortcoming is: raw material costliness, step is many, yield is low, and expensive.The United States Patent (USP) 4,824,966,4,843,166 and 5,276 of authorizing Lonza Ltd, 164 disclose the preparation method of oxyracetam and intermediate thereof.In these patents, disclosed method comprises and makes 4-(C
1-C
2)-alkoxyl group-3-pyrroline-2-one-1-base-acetic acid (C
1-C
4)-alkyl ester reacts to protect hydroxyl with trichloromethyl silane, then products therefrom is carried out to hydrogenation and amidation.According to the method, obtain racemize oxyracetam through hydrogenation reduction.Therefore, the method has the shortcoming that is not suitable for the pure oxyracetam of preparation optically-active.In addition, 4-(C1-C2)-alkoxyl group-3-pyrroline-2-one-1-base-acetic acid (C1-C4)-alkyl ester to prepare yield low.But also do not see that up till now related documents reported the preparation method of (R)-oxiracetam.
Summary of the invention
The object of the present invention is to provide the preparation method of (R)-oxiracetam that a kind of cost is low, yield is high.
The present invention seeks to be achieved through the following technical solutions:
(R) preparation method of-oxiracetam, it is characterized in that: adopting glycine ethyl ester hydrochloride is that raw material reacts under alcoholic solvent and alkaline condition with (R)-4-halogen-3-hydroxy-butyric acid ethyl ester, after filtration, with inorganic alkoxide washing, concentrated, concentrated through extraction, water again, pass into ammoniacal liquor and make the purification process of (R)-oxiracetam crude product and crude product; Described glycine ethyl ester hydrochloride first will adopt ether to dissociate into glycine ethyl ester with ammonia.
In order further to improve the yield of the present invention (R)-oxiracetam, after concentrating, also carry out column chromatography for separation through extraction, water above-mentioned, then pass into ammoniacal liquor preparation (R)-oxiracetam crude product.
For reduce reaction raw materials in reaction process of the present invention consumption, reduce costs, glycine ethyl ester hydrochloride is dissociated to improve yield and be beneficial to purification process more fully simultaneously, the present invention preferably adds glycine ethyl ester hydrochloride in ether the free of glycine ethyl ester hydrochloride, then passes into ammonia at low temperatures.
The present invention is in the free treating processes of glycine ethyl ester hydrochloride, in order further to dissociate and to obtain glycine ethyl ester fully, its temperature that passes into ammonia is 2 ℃～-5 ℃, more preferably-3 ℃～-5 ℃, wherein the usage ratio of glycine ethyl ester hydrochloride, ether and ammonia pass is 1mol: 1100～1300ml: 1.2～1.7mol.
Specifically, the present invention is that glycine ethyl ester hydrochloride is added in anhydrous diethyl ether to the free processing of glycine ethyl ester hydrochloride, ice-cold to-3 ℃～-5 ℃, pass into ammonia, filter, filtrate concentrating obtained to glycine ethyl ester, wherein the usage ratio of glycine ethyl ester hydrochloride, ether and ammonia pass is 1mol: 1250ml: 1.5mol.
For make reactant and product be easy to dissolve and react after processing facilitate, alcoholic solvent of the present invention is preferably anhydrous methanol or dehydrated alcohol.
The present invention (R)-4-halogen-3-hydroxy-butyric acid ethyl ester preferably adopts (R)-4-chloro-3-hydroxyl-ethyl butyrate; The alkali that the present invention adds preferably adopts sodium carbonate or sodium bicarbonate.
In order further to improve yield and to be more conducive to purification process, the usage ratio of the each material of the present invention is preferably glycine ethyl ester with molar ratio computing: sodium bicarbonate: (R)-4-chloro-3-hydroxyl-ethyl butyrate=1: 1～1.5: 1.2～1.8, the consumption of described dehydrated alcohol is 3～7 times of sodium bicarbonate, in weight part; More preferably, glycine ethyl ester: sodium bicarbonate: (R)-4-chloro-3-hydroxyl-ethyl butyrate=1: 1.4: 1.6, the consumption of dehydrated alcohol is sodium bicarbonate 4 times.
More particularly, the preparation of the present invention (R)-oxiracetam crude product is first glycine ethyl ester hydrochloride to be added in anhydrous diethyl ether, ice-cold extremely-4 ℃～-5 ℃, pass into ammonia, and filter, filtrate concentrating obtained to glycine ethyl ester; Then add dehydrated alcohol, sodium bicarbonate and be added dropwise to (R)-4-chloro-3-hydroxyl-ethyl butyrate, the time of described dropping (R)-4-chloro-3-hydroxyl-ethyl butyrate is 3～3.5 hours, controlling pH is 8～9, temperature of reaction is 65～75 ℃, reacts 20～30 hours; Filter, filtrate is fully washed, concentrated with methyl alcohol or ethanol, enriched material is soluble in water, then adds the chloroform of 4 times of filtrate weight to extract, and water is concentrated; Finally add again strong aqua, at 25～32 ℃, react 4～7 hours; Described glycine ethyl ester: sodium bicarbonate: (R)-4-chloro-3-hydroxyl-ethyl butyrate=1: 1～1.5: 1.2～1.8, the consumption of described dehydrated alcohol is 3～7 times of sodium bicarbonate weight.
In order further to improve the yield of the present invention's preparation (R)-oxiracetam, the preparation of the present invention (R)-oxiracetam crude product is first glycine ethyl ester hydrochloride to be added in anhydrous diethyl ether, ice-cold to-4 ℃～-5 ℃, pass into ammonia, filter, filtrate concentrating obtained to glycine ethyl ester, wherein the usage ratio of glycine ethyl ester hydrochloride, ether and ammonia pass is 1mol: 1250ml: 1.5mol; Then add dehydrated alcohol, sodium bicarbonate and described (the R)-4-chloro-3-hydroxyl-ethyl butyrate of dropping, drip 3 hours, and controlling pH is 8.5, and temperature of reaction is 75 ℃, reacts 28 hours; Filter, with the abundant wash filtrate of ethanol, concentrated, then add the chloroform of 4 times of filtrate weight to extract, water is concentrated, column chromatography for separation; Finally adding mass percentage concentration is 28% strong aqua, reacts 5 hours at 30 ℃; Described glycine ethyl ester: sodium bicarbonate: (R)-4-chloro-3-hydroxyl-ethyl butyrate=1: 1.4: 1.6, with molar ratio computing, the consumption of dehydrated alcohol was 4 times of sodium bicarbonate weight; The add-on of described 28% strong aqua is 4-8 times of above-mentioned post separated product weight.
The purification process of the thick product of the present invention is that thick product is also collected with passing through storng-acid cation exchange resin after water dissolution, then passes through in strongly basic anion exchange resin and the solution of collection, and the pH value that makes the solution of described collection completes while being neutral; Then the thick product after the solution of neutralization being collected concentrates carries out recrystallization processing.
In order to improve exchange capacity, exchange velocity, storng-acid cation exchange resin of the present invention is preferably 732# storng-acid cation exchange resin; Strongly basic anion exchange resin of the present invention is preferably 711# strongly basic anion exchange resin.
Recrystallization processing of the present invention is to adopt ethanol to carry out recrystallization processing for the first time, adopts the mixed solvent of methanol/acetone to carry out recrystallization processing for the second time.
In order further to improve the purity of the present invention (R)-oxiracetam product, in purification process process of the present invention, the aqueous solution of described thick product is pressed thick product: water=1 gram: 1.2 milliliters, the consumption of described storng-acid cation exchange resin is: described thick product: described storng-acid cation exchange resin=1 gram: 13 milliliters; Describedly with the consumption that ethanol carries out recrystallization processing be for the first time: described thick product after concentrated: ethanol=1 gram: 1.5 milliliters; Consumption in the described processing of recrystallization is for the second time: the thick product after recrystallization for the first time: methyl alcohol=1 gram: 2 milliliters, wherein in the mixed solvent of methanol/acetone, the volume ratio of methyl alcohol and acetone is 1: 2.
The present invention has following beneficial effect:
1, the main raw material that the present invention uses is (R)-4-halogen-ethyl 3-hydroxybutanoate and glycine ethyl ester hydrochloride, is commercial goods, the cheap and easy to get and environmental protection, pollution-free of raw material; Meanwhile, first the present invention carries out glycine ethyl ester hydrochloride described free processing, has effectively reduced the consumption of material in reaction, has reduced cost, the yield of reaction has also been played to positive effect simultaneously.The cost of (R)-oxiracetam prepared by the present invention is low, yield can be up to 33%, reaction conditions gentleness, cycle are short, simple to operate, be beneficial to commercial scale production, (the R)-oxiracetam product HPLC purity simultaneously making reaches more than 98.5%.
2, the present invention has adopted ion exchange resin treatment in purifying the finished product (R)-oxiracetam; compared with available technology adopting silica gel column chromatography method; although treatment effect is suitable; but ion exchange resin can repeatedly be regenerated and reuse on the one hand, has reduced cost; ion exchange resin is to carry out wash-out with pure water on the other hand; avoid with an organic solvent, pollution-free, simultaneously preferably for the large production of large-scale industrial.The majority of organic solvent toxicity that uses in the present invention is little, it is low to pollute, and the water using in last handling process is pollution-free avirulent especially, so the present invention is not only suitable for suitability for industrialized production, also meets national requirements for environmental protection.
Embodiment
Below by embodiment, the present invention is specifically described; be necessary to be pointed out that at this following examples are only used to further illustrate the present invention; can not be interpreted as limiting the scope of the invention, the person skilled in the art in this field can make some nonessential improvement and adjustment to the present invention according to the invention described above content.
Embodiment 1
(R) preparation method of-oxiracetam, carries out as follows:
1, the preparation of crude product:
(a) glycine ethyl ester hydrochloride 139.6g is joined in anhydrous diethyl ether 1250ml, ice-coldly pass into ammonia 25.5g and make glycine ethyl ester hydrochloride dissociate into glycine ethyl ester, wherein glycine ethyl ester hydrochloride: anhydrous diethyl ether: ammonia is 1mol: 1250ml: 1.5mol to-4 ℃;
(b) in above-mentioned product, add dehydrated alcohol 470ml, sodium bicarbonate 117.6g, dropping (R)-4-chloro-3-hydroxyl-ethyl butyrate 266.6g, described time for adding is 3 hours, is at 75 ℃, to react 28 hours in pH8.5, temperature;
(c) filter, with the abundant wash filtrate of ethanol, concentrated, enriched material is water-soluble, then add the chloroform of 4.5 times of filtrate weight to extract, water is concentrated, column chromatography for separation; Finally adding mass percentage concentration is 28% ammoniacal liquor, reacts and within 5 hours, make (R)-oxiracetam crude product at 30 ℃, and wherein the consumption of 28% ammoniacal liquor is 6 times of column chromatography for separation product weight;
Wherein glycine ethyl ester: sodium bicarbonate: (R)-4-chloro-3-hydroxyl-ethyl butyrate=1: 1.4: 1.6, with molar ratio computing, the consumption of dehydrated alcohol was 4 times of sodium bicarbonate weight;
2, the purifying of crude product:
(a), with the above-mentioned crude product making of water dissolution, by 732# storng-acid cation exchange resin, then neutralize and collect solution, concentrated by 711# strongly basic anion exchange resin; Described crude product: water=1 gram: 1.2 milliliters, described thick product: described storng-acid cation exchange resin=1 gram: 13 milliliters;
(b) then adopt ethanol to carry out recrystallization processing for the first time above-mentioned crude product after concentrating by ion exchange resin, adopt the mixed solvent of methanol/acetone to carry out recrystallization processing for the second time and make (R)-oxiracetam product; Described by thick product concentrated after ion exchange resin: ethanol=1 gram: 1.5 milliliters; Thick product after described recrystallization for the first time: methyl alcohol=1 gram: 2 milliliters, wherein in the mixed solvent of methanol/acetone, the volume ratio of methyl alcohol and acetone is 1: 2.
The HPLC purity of (the R)-oxiracetam product finally making reaches 99.5%, and yield is up to 33%.
Embodiment 2
(R) preparation method of-oxiracetam, carries out as follows:
1, the preparation of crude product:
(a) glycine ethyl ester hydrochloride is joined in anhydrous diethyl ether, ice-coldly pass into ammonia and make glycine ethyl ester hydrochloride dissociate into glycine ethyl ester, wherein glycine ethyl ester hydrochloride: anhydrous diethyl ether: ammonia is 1mol: 1300ml: 1.2mol to-4 ℃;
(b) in above-mentioned product, add anhydrous methanol, sodium carbonate, the iodo-3-hydroxy-butyric acid of (R)-4-ethyl ester, be at 65 ℃, to react 20 hours in pH8, temperature;
(c) filter, with the abundant wash filtrate of ethanol, concentrated, enriched material is water-soluble, then add the ethyl acetate of 5 times of filtrate weight to extract, water is concentrated, column chromatography for separation; Finally adding mass percentage concentration is 27% ammoniacal liquor, reacts and within 7 hours, make (R)-Esomeprazole crude product at 25 ℃, and wherein the consumption of 27% ammoniacal liquor is 8 times of column chromatography for separation product weight; Wherein glycine ethyl ester: sodium carbonate: the iodo-3-hydroxy-butyric acid of (R)-4-ethyl ester=1: 1.5: 1.8, with molar ratio computing, the consumption of anhydrous methanol was 7 times of sodium carbonate weight;
2, the purifying of crude product:
(a), with the above-mentioned crude product making of water dissolution, by 001 × 7 strongly acidic styrene type cation exchange resin, then neutralize and collect solution, concentrated by 201 × 7 basicity styrene series anion exchange resins; Described crude product: water=1 gram: 0.6 milliliter, described thick product: described storng-acid cation exchange resin=1 gram: 10 milliliters;
(b) then adopt ethanol to carry out recrystallization processing for the first time above-mentioned crude product after concentrating by ion exchange resin, adopt the mixed solvent of methanol/acetone to carry out recrystallization processing for the second time and make (R)-oxiracetam product; Described by thick product concentrated after ion exchange resin: ethanol=1 gram: 1.5 milliliters; Thick product after described recrystallization for the first time: methyl alcohol=1 gram: 1 milliliter, wherein in the mixed solvent of methanol/acetone, the volume ratio of methyl alcohol and acetone is 1: 2.
The HPLC purity of (the R)-oxiracetam product finally making reaches 99.2%, and yield reaches 28%.
Embodiment 3
(R) preparation method of-oxiracetam, carries out as follows:
1, the preparation of crude product:
(a) glycine ethyl ester hydrochloride is suspended in chemical pure ether, then passes into ammonia and make glycine ethyl ester hydrochloride dissociate into glycine ethyl ester;
(b) in above-mentioned product, add dehydrated alcohol, sodium bicarbonate, the bromo-3-hydroxy-butyric acid of dropping (R)-4-ethyl ester, described time for adding is 3.5 hours, is at 70 ℃, to react 20～26 hours in pH9, temperature;
(c) then filter, with the abundant wash filtrate of ethanol, concentrated, enriched material is water-soluble, then add the chloroform of 4 times of filtrate weight to extract, water is concentrated; Finally adding mass percentage concentration is 26% ammoniacal liquor, reacts and within 6 hours, make (R)-oxiracetam crude product at 28 ℃;
Wherein glycine ethyl ester: sodium bicarbonate: (R)-4-is bromo--3-hydroxy-butyric acid ethyl ester=1: 1: 1.2, with molar ratio computing, the consumption of dehydrated alcohol was 3 times of sodium bicarbonate weight;
2, the purifying of crude product:
(a), with the above-mentioned crude product making of water dissolution, by 732# storng-acid cation exchange resin, then neutralize and collect solution, concentrated by 711# strongly basic anion exchange resin; Described crude product: water=1 gram: 0.6 milliliter, described thick product: described storng-acid cation exchange resin=1 gram: 10 milliliters;
(b) then adopt ethanol to carry out recrystallization processing for the first time above-mentioned crude product after concentrating by ion exchange resin, adopt the mixed solvent of methanol/acetone to carry out recrystallization processing for the second time and make (R)-oxiracetam product; Described by thick product concentrated after ion exchange resin: ethanol=1 gram: 1.5 milliliters; Thick product after described recrystallization for the first time: methyl alcohol=1 gram: 2 milliliters, wherein in the mixed solvent of methanol/acetone, the volume ratio of methyl alcohol and acetone is 1: 3.
The HPLC purity of (the R)-oxiracetam product finally making reaches 99.3%, and yield is up to 26%.
Embodiment 4～8:
A kind of preparation method of (R)-oxiracetam, is undertaken by following material and processing parameter, and all the other are with embodiment 1.
The HPLC purity of (R)-oxiracetam product that above embodiment finally makes reaches more than 98.5%～99.26%, and yield reaches 28%～33%.
Claims (2)
1. the preparation method of a (R)-oxiracetam, it is characterized in that: the preparation of described (R)-oxiracetam crude product is first glycine ethyl ester hydrochloride to be added in anhydrous diethyl ether, ice-cold to-4 ℃～-5 ℃, pass into ammonia, filter, filtrate concentrating obtained to glycine ethyl ester, wherein the usage ratio of glycine ethyl ester hydrochloride, ether and ammonia pass is 1mol:1100～1300ml:1.2～1.7 mol; Then add dehydrated alcohol, sodium bicarbonate and dropping (R)-4-chloro-3-hydroxyl-ethyl butyrate, the time of described dropping (R)-4-chloro-3-hydroxyl-ethyl butyrate is 3～3.5 hours, controlling pH is 8～9, temperature of reaction is 65～75 ℃, reacts 20～30 hours; Filter, filter residue methyl alcohol or ethanol are fully washed, concentrated, enriched material is soluble in water, then adds the chloroform of 4 times of filtrate weight to extract, and after water is concentrated, column chromatography for separation obtains (R)-4-hydroxyl-2-OXo-1-pyrrolidine ethyl acetate; Finally add again 28% strong aqua, at 25～32 ℃, react 4～7 hours; Described glycine ethyl ester: sodium bicarbonate: (R)-4-chloro-3-hydroxyl-ethyl butyrate=1:1～1.5:1.2～1.8, the consumption of described dehydrated alcohol is 3～7 times of sodium bicarbonate weight; The add-on of described 28% strong aqua is 4-8 times of described column chromatography for separation product weight; The purification process of described thick product is that thick product is also collected with passing through storng-acid cation exchange resin after water dissolution, then passes through in strongly basic anion exchange resin and the solution of collection, and the pH value that makes the solution of described collection completes while being neutral; Then the thick product after the solution of neutralization being collected concentrates carries out recrystallization processing;
Described recrystallization processing is to adopt ethanol to carry out recrystallization processing for the first time, adopts the mixed solvent of methanol/acetone to carry out recrystallization processing for the second time;
Describedly with the consumption that ethanol carries out recrystallization processing be for the first time: described thick product after concentrated: ethanol=1 gram: 1.5 milliliters; Consumption in the described processing of recrystallization is for the second time: the thick product after recrystallization for the first time: methyl alcohol=1 gram: 2 milliliters, wherein in the mixed solvent of methanol/acetone, the volume ratio of methyl alcohol and acetone is 1:2.
2. preparation method as claimed in claim 1, is characterized in that: described storng-acid cation exchange resin is 732# storng-acid cation exchange resin, and described strongly basic anion exchange resin is 711# strongly basic anion exchange resin; The aqueous solution of described thick product is pressed thick product: water=1 gram: 1.2 milliliters, the consumption of described storng-acid cation exchange resin is: described thick product: described storng-acid cation exchange resin=1 gram: 13 milliliters.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110024526.XA CN102603607B (en) | 2011-01-21 | 2011-01-21 | Preparation method of (R)-oxiracetam |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110024526.XA CN102603607B (en) | 2011-01-21 | 2011-01-21 | Preparation method of (R)-oxiracetam |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102603607A CN102603607A (en) | 2012-07-25 |
| CN102603607B true CN102603607B (en) | 2014-06-11 |
Family
ID=46521449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110024526.XA Active CN102603607B (en) | 2011-01-21 | 2011-01-21 | Preparation method of (R)-oxiracetam |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102603607B (en) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105330582B (en) * | 2014-08-07 | 2018-08-07 | 重庆润泽医药有限公司 | (R) preparation method of-Esomeprazole |
| KR20170137910A (en) * | 2015-05-18 | 2017-12-13 | 충칭 룬즈 파마슈티컬 컴퍼니 리미티드. | Application of R-oxylacetam in pharmaceutical field |
| EP3530272A4 (en) * | 2016-10-24 | 2020-03-25 | Chongqing Runze Pharmaceutical Company Limited | Novel crystalline form of dextral oxiracetam, preparation method therefor and use thereof |
| JP2019531323A (en) * | 2016-10-24 | 2019-10-31 | チョンキン ランゼ ファーマスーティカル カンパニー リミテッド | (R) -4-Hydroxy-2-oxo-1-pyrrolidineacetamide crystal form, preparation method, use |
| EP3530271A4 (en) | 2016-10-24 | 2020-03-25 | Chongqing Runze Pharmaceutical Company Limited | Crystalline form ii of dextral oxiracetam, preparation method therefor and use thereof |
| CN108299267A (en) * | 2017-01-12 | 2018-07-20 | 重庆润泽医药有限公司 | (R) crystal form and its preparation method and application of -4- hydroxyls -2- oxygen -1- pyrrolidine acetamides |
| CN108299268A (en) * | 2017-01-12 | 2018-07-20 | 重庆润泽医药有限公司 | The preparation method of one kind (R) -4- hydroxyl -2- oxygen -1- pyrrolidine acetamide crystal forms |
| CN109251157A (en) * | 2017-07-13 | 2019-01-22 | 重庆润泽医药有限公司 | (R)-Esomeprazole preparation method |
| CN110314138A (en) * | 2018-03-29 | 2019-10-11 | 重庆润泽医药有限公司 | Freeze-dried composition and preparation method thereof comprising dextrorotation oxiracetam |
| CN110314140A (en) * | 2018-03-29 | 2019-10-11 | 重庆润泽医药有限公司 | The freeze-dried composition and preparation method thereof of 1/2 hydrate of Oxiracetam containing dextrorotation |
| CN110314143A (en) * | 2018-03-29 | 2019-10-11 | 重庆润泽医药有限公司 | Injection dextrorotation Oxiracetam lyophilized preparation and preparation method thereof |
| CN110314141A (en) * | 2018-03-29 | 2019-10-11 | 重庆润泽医药有限公司 | A kind of dextrorotation oxiracetam freeze drying powder injection and preparation method thereof |
| CN110314144A (en) * | 2018-03-29 | 2019-10-11 | 重庆润泽医药有限公司 | The good dextrorotation Oxiracetam freeze drying powder injection and preparation method thereof of solubility |
| CN110314142A (en) * | 2018-03-29 | 2019-10-11 | 重庆润泽医药有限公司 | A kind of no crystal water dextrorotation oxiracetam freeze drying powder injection and preparation method thereof |
| CN110314139A (en) * | 2018-03-29 | 2019-10-11 | 重庆润泽医药有限公司 | The good dextrorotation oxiracetam lyophilized preparation and preparation method thereof of solubility |
| CN110327301A (en) * | 2018-03-29 | 2019-10-15 | 重庆润泽医药有限公司 | The good dextrorotation Oxiracetam freeze drying powder injection and preparation method thereof of stability |
| CN110384660A (en) * | 2018-04-17 | 2019-10-29 | 重庆润泽医药有限公司 | Injection dextrorotation Oxiracetam aseptic powdery and preparation method thereof |
| CN110384662A (en) * | 2018-04-17 | 2019-10-29 | 重庆润泽医药有限公司 | A kind of injection dextrorotation oxiracetam and the composition of histidine and preparation method thereof |
| CN110384659A (en) * | 2018-04-17 | 2019-10-29 | 重庆润泽医药有限公司 | Injection dextrorotation oxiracetam powder-injection and preparation method thereof |
| CN110384661A (en) * | 2018-04-17 | 2019-10-29 | 重庆润泽医药有限公司 | The good dextrorotation oxiracetam aseptic powdery and preparation method thereof of stability |
| CN110384663A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | Dextrorotation oxiracetam particle of good fluidity and preparation method thereof |
| CN110384677A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | The good dextrorotation oxiracetam capsule and preparation method thereof of dissolution rate |
| CN110384673A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | Dextrorotation oxiracetam capsule and preparation method thereof |
| CN110384664A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | Dextrorotation oxiracetam enteric coated particles and preparation method thereof |
| CN110384674A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | Dextrorotation oxiracetam capsule and preparation method thereof |
| CN110384676A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | The good dextrorotation oxiracetam capsule and preparation method thereof of stability |
| CN110384671A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | Fluidized bed granulation prepares dextrorotation oxiracetam capsule and preparation method thereof |
| CN110384672A (en) * | 2018-04-20 | 2019-10-29 | 重庆润泽医药有限公司 | The good dextrorotation oxiracetam capsule and preparation method thereof of stability |
| CN110384666A (en) * | 2018-04-23 | 2019-10-29 | 重庆润泽医药有限公司 | A kind of method of wet granule compression tablet preparation dextrorotation Oxiracetam tablet |
| CN110384667A (en) * | 2018-04-23 | 2019-10-29 | 重庆润泽医药有限公司 | The method of dry granulation tabletting preparation dextrorotation Orazitan dispersion tablet |
| CN110384665A (en) * | 2018-04-23 | 2019-10-29 | 重庆润泽医药有限公司 | Crystal type dextrorotation oxiracetam tablet and preparation method thereof |
| CN110393706A (en) * | 2018-04-24 | 2019-11-01 | 重庆润泽医药有限公司 | Dextrorotation oxiracetam enteric coatel tablets and preparation method thereof |
| CN110393707A (en) * | 2018-04-24 | 2019-11-01 | 重庆润泽医药有限公司 | Dextrorotation Oxiracetam enteric coatel tablets and preparation method thereof |
| CN110393704A (en) * | 2018-04-24 | 2019-11-01 | 重庆润泽医药有限公司 | A kind of dextrorotation Orazitan dispersion tablet and preparation method thereof |
| CN110393802A (en) * | 2018-04-24 | 2019-11-01 | 重庆润泽医药有限公司 | Dextrorotation oxiracetam dispersible tablet and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1956953A (en) * | 2004-05-25 | 2007-05-02 | 安国药品株式会社 | Process for the preparation of optically pure 4-hydroxy-2-oxo-1-pyrrolidine acetamide |
| CN101367757A (en) * | 2008-10-13 | 2009-02-18 | 重庆润泽医疗器械有限公司 | Preparation method for (S)-4-hydroxyl-2-oxo-1-pyrrolidine ethanamide |
-
2011
- 2011-01-21 CN CN201110024526.XA patent/CN102603607B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1956953A (en) * | 2004-05-25 | 2007-05-02 | 安国药品株式会社 | Process for the preparation of optically pure 4-hydroxy-2-oxo-1-pyrrolidine acetamide |
| CN101367757A (en) * | 2008-10-13 | 2009-02-18 | 重庆润泽医疗器械有限公司 | Preparation method for (S)-4-hydroxyl-2-oxo-1-pyrrolidine ethanamide |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102603607A (en) | 2012-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102603607B (en) | Preparation method of (R)-oxiracetam | |
| CN101619069A (en) | Preparation method of cefotiam hexetil hydrochloride | |
| CN102766185A (en) | Method for respectively recovering ursodesoxycholic acid and chenodeoxycholic acid from ursodesoxycholic acid waste mother liquor | |
| CN102603603B (en) | Method for preparing (S)-oxiracetam | |
| CN101928311A (en) | Preparation method of 1-N-ethyl gentamicin Cla | |
| CN107383085A (en) | A kind of chemical synthesis process of L α Choline Glycerophosphates | |
| CN102603595B (en) | Preparation method of (S)-oxiracetam | |
| CN102603594B (en) | Preparation method of (S)-oxiracetam | |
| CN103214421B (en) | The industrialized preparing process of 2-sulfydryl-1-Methylimidazole | |
| CN103113250A (en) | Preparation method of D-para hydroxybenzene glycine methyl ester | |
| CN104945436A (en) | Minodronic acid preparing method | |
| CN102603602B (en) | Preparation method of oxiracetam | |
| CN102603599B (en) | Method for preparing (S)-oxiracetam | |
| CN102603605B (en) | Preparation method of (S)-4-hydroxy-2-oxo-1-pyrrolidineacetamide | |
| CN102603604B (en) | Preparation method of (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide | |
| CN102127127A (en) | Kanamycin extracting process | |
| CN102603596B (en) | Preparation method of (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide | |
| CN102690222A (en) | Preparation method of (R,S)-4-hydroxy-2-oxo-1-pyrrolidineacetamide | |
| CN102603600A (en) | Method for preparing (S)-oxiracetam | |
| CN102603598B (en) | Preparation method of (S)-4-hydroxy-2-oxo-1-pyrrolidineacetamide | |
| CN103739538B (en) | A kind of preparation method of (S)-Olaxiracetam | |
| CN101845053A (en) | Method for separating and purifying amoxicillin trihydrate | |
| CN103724250A (en) | Preparation method of (S)-oxiracetam | |
| WO2013159283A1 (en) | Method for preparing (s)-oxiracetam | |
| CN109438356A (en) | A kind of purification process of Prochloraz raw medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 400042 Chongqing city Yubei District Qinye Road No. 9 Applicant after: Chongqing Runze Pharmaceutical Co., Ltd. Address before: 401120 Chongqing city Yubei District Shuangfeng Bridge Street Airport Road No. 296 Building 1 yuan and 7 2- store Applicant before: Chongqing Runze Medical Instruments Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: CHONGQING RUNZE MEDICAL INSTRUMENTS LTD. TO: CHONGQING RUNZE PHARMACEUTICAL CO., LTD. |
|
| ASS | Succession or assignment of patent right |
Owner name: WENZHOU ZHICHUANG TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: CHONGQING RUNZE PHARMACEUTICAL CO., LTD. Effective date: 20140115 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 400042 YUBEI, CHONGQING TO: 325000 WENZHOU, ZHEJIANG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20140115 Address after: 325000 Zhejiang city of Wenzhou province Longwan high tech Industrial Park, Aojiang Road No. 81 building two floor B Applicant after: WENZHOU ZHICHUANG TECHNOLOGY CO., LTD. Address before: 400042 Chongqing city Yubei District Qinye Road No. 9 Applicant before: Chongqing Runze Pharmaceutical Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ye Lei Inventor before: Ye Lei Inventor before: Chen Yuying Inventor before: Li Kun Inventor before: Rong Zuyuan Inventor before: Yu Yuanyuan Inventor before: Ping Yuan |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: YE LEI CHEN YUYING LI KUN RONG ZUYUAN YU YUANYUAN PING YUAN TO: YE LEI |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20170816 Address after: 400042 Chongqing city Yubei District Qinye Road No. 9 Patentee after: Chongqing Runze Pharmaceutical Co., Ltd. Address before: 325000 Zhejiang city of Wenzhou province Longwan high tech Industrial Park, Aojiang Road No. 81 building two floor B Patentee before: WENZHOU ZHICHUANG TECHNOLOGY CO., LTD. |
|
| TR01 | Transfer of patent right |